title: Treat to target-what is realistic in Australian practice today?
authors.affiliation: Department of Medicine, University of Otago, Christchurch, New Zealand. Richard.Gearry@cdhb.health.nz.
authors.forename: Richard B
authors.initials: RB
authors.lastname: Gearry
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001315:Australia; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D000069285:Infliximab / Q000627:therapeutic use; D019804:Mesalamine / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012307:Risk Factors; D012720:Severity of Illness Index; D013997:Time Factors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D019804:Mesalamine; C543529:vedolizumab; D000069285:Infliximab; D011241:Prednisone